<DOC>
	<DOCNO>NCT01809704</DOCNO>
	<brief_summary>To demonstrate clinical substantial equivalence DRI OCT-1 comparable commercially available Cirrus</brief_summary>
	<brief_title>Clinical Validation New OCT System</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Normal Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site normal eye ( eye without pathology ) 4 . IOP â‰¤ 21 mmHg bilaterally 5 . BCVA 20/40 well bilaterally 6 . Both eye must free eye disease Exclusion Criteria Normal Group 1 . Subjects unable tolerate ophthalmic imaging 2 . Subject ocular medium sufficiently clear obtain acceptable OCT image 3 . HFA visual field ( 242 Sita Standard , white white ) result abnormal , define GHT 'Outside Normal Limits ' and/or PSD &lt; 1 % 4 . HFA visual field ( 242 Sita Standard , white white ) result unreliable ( base manufacturer 's recommendation ) , define fixation loss &gt; 33 % false positives &gt; 25 % , false negative &gt; 25 % 5 . Presence ocular pathology except cataract 6 . Previous ocular surgery laser treatment uncomplicated refractive procedure cataract surgery perform within six month prior study scan 7 . Narrow angle 8 . History leukemia , dementia multiple sclerosis 9 . Concomitant use hydroxychloroquine chloroquine Inclusion Criteria Glaucoma Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site glaucoma 4 . BCVA 20/40 good study eye 5 . HFA visual field ( 242 Sita Standard , white white ) result abnormal , define GHT 'Outside Normal Limits ' and/or PSD &lt; 1 % study eye Exclusion Criteria Glaucoma Group 1 . Subjects unable tolerate ophthalmic imaging 2 . Subject ocular medium sufficiently clear obtain acceptable OCT image 3 . HFA visual field ( 242 Sita Standard , white white ) result unreliable , defined fixation loss &gt; 33 % false positives &gt; 25 % , false negative &gt; 25 % study eye 4 . Presence ocular pathology except glaucoma study eye 5 . Previous ocular surgery laser treatment uncomplicated procedure perform within six month prior study scan study eye 6 . History leukemia , dementia multiple sclerosis 7 . Concomitant use hydroxychloroquine chloroquine Inclusion Criteria Retina Disease Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site retinal disease 4 . IOP &lt; = 21 mmHg study eye 5 . BCVA 20/400 good study eye 6 . Diagnosis type retinal pathology investigator , may include , limited : Macular Degeneration , Diabetic Macular Edema , Diabetic Retinopathy , Macular Hole , Epiretinal Membrane , Cystoid Macula Edema , others Exclusion Criteria Retinal Disease Group 1 . Subjects unable tolerate ophthalmic imaging 2 . Subject ocular medium sufficiently clear obtain acceptable OCT image 3 . Presence glaucoma ocular pathology Retinal pathology ( e.g. , cornea pathology ) study eye 4 . Previous ocular surgery laser treatment uncomplicated procedure perform within six month prior study scan study eye 5 . Narrow angle study eye 6 . History leukemia , dementia multiple sclerosis 7 . Concomitant use hydroxychloroquine chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>